This comprehensive report provides an in-depth analysis of the Asia-Pacific vaccine market, detailing its significant growth trajectory and evolving competitive landscape. The study examines various segments, including vaccine compositions, types, age groups, and administration routes, while evaluating key applications such as influenza and hepatitis. By analyzing market drivers, technological advancements, and strategic industry trends, the research offers stakeholders actionable intelligence to navigate the complex regulatory environment and capitalize on emerging opportunities across the region.

Market Overview

The Asia-Pacific Vaccine Market reached US$ 12.33 billion in 2023 and is expected to reach US$ 17.82 billion by 2031, growing with a CAGR of 6.10% during the forecast period 2026-2031.

The Asia-Pacific Vaccine Market emerges as a key focus in DataM Intelligence's latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Asia-Pacific Vaccine Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

Market Segmentation

By Composition

• Combination Vaccines
• Mono Vaccines

By Type

• CD30 Antibodies
• Live-Attenuated Vaccines
• Inactivated Vaccines
• Toxoid Vaccines
• Others

By Age Group

• Pediatrics
• Adults

By Route of Administration

• Injectables
• Oral
• Others

By Application

• Pneumococcal Disease
• Measles
• Mumps & Varicella (Chickenpox)
• DPT (Diphtheria, Pertussis, Tetanus)
• Hepatitis
• Influenza
• Typhoid
• Meningococcal Disease
• Rabies
• Japanese Encephalitis
• Yellow Fever
• Others

By End-User

• Hospitals & Specialty Clinics
• Vaccination Centers
• Others

Scope of the Report

This report provides comprehensive coverage including:

• Go-to-market Strategy: Insights into market entry and expansion.
• Market Performance: A neutral perspective on overall market performance.
• Comprehensive Analysis: Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
• Regional Analysis: Customized regional/country reports as per request and country level analysis.
• Growth Opportunities: Potential & niche segments and regions exhibiting promising growth covered.
• Market Metrics: Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process

Both primary and secondary data sources have been used in the global Asia-Pacific Vaccine Market research report. During the research process, a wide range of industry-affecting factors are examined, including:

• Governmental regulations
• Market conditions
• Competitive levels
• Historical data
• Market situation
• Technological advancements
• Upcoming developments in related businesses
• Market volatility
• Prospects
• Potential barriers and challenges

• 1 Methodology and Scope

  • 1.1 Research Methodology

  • 1.2 Research Objective and Scope of the Report

• 2 Definition and Overview

• 3 Executive Summary

  • 3.1 Snippet by Composition

  • 3.2 Snippet by Type

  • 3.3 Snippet by Age Group

  • 3.4 Snippet by Route of Administration

  • 3.5 Snippet by Application

  • 3.6 Snippet by End-User

• 4 Dynamics

  • 4.1 Impacting Factors

    • 4.1.1 Drivers

      • 4.1.1.1 Increasing Prevalence of Infectious Diseases
      • 4.1.1.2 XX

    • 4.1.2 Restraints

      • 4.1.2.1 Stringent Regulatory Requirements

    • 4.1.3 Opportunity

    • 4.1.4 Impact Analysis

• 5 Industry Analysis

  • 5.1 Porter’s Five Force Analysis

  • 5.2 Supply Chain Analysis

  • 5.3 Pricing Analysis

  • 5.4 Regulatory Analysis

• 6 By Composition

  • 6.1 Introduction

    • 6.1.1 Analysis and Y-o-Y Growth Analysis (%), By Composition

    • 6.1.2 Market Attractiveness Index, By Composition

  • 6.2 Combination Vaccines*

    • 6.2.1 Introduction

    • 6.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)

  • 6.3 Mono Vaccines

• 7 By Type

  • 7.1 Introduction

    • 7.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

    • 7.1.2 Market Attractiveness Index, By Type

  • 7.2 CD30 Antibodies *

    • 7.2.1 Introduction

    • 7.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)

  • 7.3 Live-Attenuated Vaccines

  • 7.4 Inactivated Vaccines

  • 7.5 Toxoid Vaccines

  • 7.6 Others

• 8 By Age Group

  • 8.1 Introduction

    • 8.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group

    • 8.1.2 Market Attractiveness Index, By Age Group

  • 8.2 Pediatrics*

    • 8.2.1 Introduction

    • 8.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)

  • 8.3 Adults

• 9 By Route of Administration

  • 9.1 Introduction

    • 9.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

    • 9.1.2 Market Attractiveness Index, By Route of Administration

  • 9.2 Injectables*

    • 9.2.1 Introduction

    • 9.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)

  • 9.3 Oral

  • 9.4 Others

• 10 By Application

  • 10.1 Introduction

    • 10.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

    • 10.1.2 Market Attractiveness Index, By Application

  • 10.2 Pneumococcal Disease*

    • 10.2.1 Introduction

    • 10.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)

  • 10.3 Pneumococcal Disease

  • 10.4 Measles

  • 10.5 Mumps & Varicella (Chickenpox)

  • 10.6 DPT (Diphtheria, Pertussis, Tetanus)

  • 10.7 Hepatitis

  • 10.8 Influenza

  • 10.9 Typhoid

  • 10.10 Meningococcal Disease

  • 10.11 Rabies

  • 10.12 Japanese Encephalitis

  • 10.13 Yellow Fever

  • 10.14 Others

• 11 By End-User

  • 11.1 Introduction

    • 11.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

    • 11.1.2 Market Attractiveness Index, By End-User

  • 11.2 Hospitals & Specialty Clinics*

    • 11.2.1 Introduction

    • 11.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)

  • 11.3 Vaccination Centers

  • 11.4 Others

• 12 Asia-Pacific

  • 12.1 Introduction

  • 12.2 Key Region-Specific Dynamics

  • 12.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Composition

  • 12.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

  • 12.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group

  • 12.6 Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

  • 12.7 Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

  • 12.8 Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

  • 12.9 Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

    • 12.9.1 China

    • 12.9.2 India

    • 12.9.3 Japan

    • 12.9.4 South Korea

    • 12.9.5 Australia

    • 12.9.6 Indonesia

    • 12.9.7 Malaysia

    • 12.9.8 Singapore

    • 12.9.9 Thailand

    • 12.9.10 Rest of Asia-Pacific

• 13 Competitive Landscape

  • 13.1 Competitive Scenario

  • 13.2 Market Positioning/Share Analysis

  • 13.3 Mergers and Acquisitions Analysis

• 14 Company Profiles

  • 14.1 Serum Institute of India Pvt. Ltd. *

    • 14.1.1 Company Overview

    • 14.1.2 Product Portfolio and Description

    • 14.1.3 Financial Overview

    • 14.1.4 Key Developments

  • 14.2 Bharat Biotech

  • 14.3 CSL

  • 14.4 GSK plc

  • 14.5 Pfizer Inc

  • 14.6 Biological E Limited

  • 14.7 Takeda Pharmaceutical Company Limited

  • 14.8 Sanofi

  • 14.9 Merck & Co., Inc

  • 14.10 Abbott (*LIST NOT EXHAUSTIVE)

• 15 Appendix

  • 15.1 About Us and Services

  • 15.2 Contact Us